Grace Larry
Direktor/Vorstandsmitglied bei Generate Biomedicines, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Geoffrey von Maltzahn | M | 43 |
Generate Biomedicines, Inc.
 Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | 6 Jahre |
| Bill Winters | M | 62 | 11 Jahre | |
| Gevorg Grigoryan | M | - |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | 6 Jahre |
| Chas Pulido | M | - |
Alix Ventures
 Alix Ventures Investment ManagersFinance Alix Ventures is an venture capital firm founded in 2019 by Chas Pulido. The firm is headquartered in San Francisco, California. | 5 Jahre |
| Linda Louie | F | - | 4 Jahre | |
| Peter Griffith | M | 65 | 5 Jahre | |
| Avak Kahvejian | M | 48 |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | 6 Jahre |
| Molly Gibson | F | - |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | 6 Jahre |
| Charles Sawyers | M | 65 | 11 Jahre | |
| Noubar Afeyan | M | 60 |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | - |
| Amy Miles | F | 57 | 4 Jahre | |
| Hans Jörg Reinhardt | M | 68 | 11 Jahre | |
| Jane Mendillo | F | 65 |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | 2 Jahre |
| Daniel Delubac | M | - |
Alix Ventures
Alix Ventures Investment ManagersFinance Alix Ventures is an venture capital firm founded in 2019 by Chas Pulido. The firm is headquartered in San Francisco, California. | - |
| Jessica Chao | F | - |
Alix Ventures
Alix Ventures Investment ManagersFinance Alix Ventures is an venture capital firm founded in 2019 by Chas Pulido. The firm is headquartered in San Francisco, California. | 5 Jahre |
| Eric Dai | M | - |
Alix Ventures
Alix Ventures Investment ManagersFinance Alix Ventures is an venture capital firm founded in 2019 by Chas Pulido. The firm is headquartered in San Francisco, California. | 4 Jahre |
| Susan Sweeney | F | - | 5 Jahre | |
| Jacob Becraft | M | - |
Alix Ventures
Alix Ventures Investment ManagersFinance Alix Ventures is an venture capital firm founded in 2019 by Chas Pulido. The firm is headquartered in San Francisco, California. | - |
| Frances Arnold | M | 67 |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | 5 Jahre |
| Michael Nally | M | 48 |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | 6 Jahre |
| Michael Nohaile | M | 55 |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | - |
| Eric Anderson | M | - |
Kellogg School of Management
| 21 Jahre |
| Mark A. Pulido | M | 72 |
Alix Ventures
Alix Ventures Investment ManagersFinance Alix Ventures is an venture capital firm founded in 2019 by Chas Pulido. The firm is headquartered in San Francisco, California. | 4 Jahre |
| Brian Fiske | M | - |
Alix Ventures
Alix Ventures Investment ManagersFinance Alix Ventures is an venture capital firm founded in 2019 by Chas Pulido. The firm is headquartered in San Francisco, California. | 5 Jahre |
| Gary Pisano | M | 62 |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | - |
| Stéphane Bancel | M | 51 |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | - |
| Charlotte Pamer-Wieser | M | - | 13 Jahre | |
| Snyder Alexandra | M | - |
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. BiotechnologyHealth Technology Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Paul Eisenberg | M | - | 14 Jahre | |
| Rebecca M. Henderson | M | 63 | 11 Jahre | |
| Drew Edwards | M | - |
Northwestern University School of Law
Kellogg School of Management
| 4 Jahre |
| David C. Marek | M | 59 | - | |
| Will Price | M | - |
Kellogg School of Management
| 2 Jahre |
| Nazar Yasin | M | - |
Northwestern University School of Law
Kellogg School of Management
| 3 Jahre |
| Paras P. Maniar | M | - |
Northwestern University School of Law
Kellogg School of Management
| 3 Jahre |
| Susanne Antonie Schaffert | M | 57 | 2 Jahre | |
| Enrico Cipro Vanni | M | 73 | - | |
| Dimitri Azar | M | 65 | 7 Jahre | |
| David Meline | M | 66 | 6 Jahre | |
| Gabe Greenbaum | M | - |
Northwestern University School of Law
Kellogg School of Management
| 3 Jahre |
| Cynthia Patton | F | 62 | 15 Jahre | |
| Verena A. Briner | M | 72 | 3 Jahre | |
| Suzana Fagundes Ribeiro de Oliveira | F | - |
Kellogg School of Management
Northwestern University School of Law
| 3 Jahre |
| Ivneet Bhullar | M | - | 2 Jahre | |
| Sebastian Arango | M | - |
Northwestern University School of Law
Kellogg School of Management
| 3 Jahre |
| Shannon Klinger | M | 53 | 10 Jahre | |
| Kim Stratton | F | 62 | 3 Jahre | |
| Alexandre F. Jetzer-Chung | M | 83 | 15 Jahre | |
| Frank Herringer | M | 81 | 15 Jahre | |
| Robert Piconi | M | 53 |
Kellogg School of Management
| 6 Jahre |
| Daniel Vasella | M | 70 | 17 Jahre | |
| Priti Choksi | F | - |
Kellogg School of Management
| 1 Jahre |
| Victor Biryukov | M | - |
Northwestern University School of Law
| 3 Jahre |
| Michael Aingorn | M | - |
Kellogg School of Management
| 2 Jahre |
| Rod Stoddard | M | - |
Kellogg School of Management
| 2 Jahre |
| Alex Stimpson | M | - |
Kellogg School of Management
| 2 Jahre |
| Jaska Marianne de Bakker | F | 53 |
Kellogg School of Management
| 2 Jahre |
| Garrett Ryan | M | - |
Kellogg School of Management
| 2 Jahre |
| Sumio Matsumoto | M | 59 |
Kellogg School of Management
| 1 Jahre |
| Sridevi Badiga | F | - |
Kellogg School of Management
| 2 Jahre |
| Natalie Burkart | F | - |
Kellogg School of Management
| 3 Jahre |
| Ami Fadia | F | - |
Kellogg School of Management
| 2 Jahre |
| Jonathan M. Harris | M | - |
Kellogg School of Management
| 2 Jahre |
| Jeffrey C. Johnson | M | 52 |
Kellogg School of Management
| 2 Jahre |
| Kristin Yarema | M | 53 | 7 Jahre | |
| João Miguel Gaspar da Silva | M | 48 |
Kellogg School of Management
| 2 Jahre |
| Diana Landa | F | - | 2 Jahre | |
| Christopher J. DeRespino | M | 43 | 3 Jahre | |
| Sarah Korman | M | 44 | 5 Jahre | |
| Jyoti Black | F | - |
Kellogg School of Management
| 12 Jahre |
| Matt R. Evans | M | - |
Kellogg School of Management
| 4 Jahre |
| Ying Li Ma | M | 50 | 1 Jahre | |
| Mark Burggraaff | M | - |
Kellogg School of Management
| 2 Jahre |
| Brock Evan Moseley | M | - |
Kellogg School of Management
| 2 Jahre |
| Scott M. Wasserman | M | - | 14 Jahre | |
| Chris McLaughlin | M | - |
Kellogg School of Management
| 2 Jahre |
| Hon Tang | M | 55 |
Kellogg School of Management
| 2 Jahre |
| Edward Jennings | M | 54 |
Kellogg School of Management
| 2 Jahre |
| Perry Williams | M | - |
Kellogg School of Management
| 1 Jahre |
| Jim Clark | M | - |
Kellogg School of Management
| 2 Jahre |
| William Christian Dauphinais | M | - |
Kellogg School of Management
| 4 Jahre |
| Matt Compton | M | 53 |
Kellogg School of Management
| 2 Jahre |
| Gigi Levy-Weiss | M | 52 |
Kellogg School of Management
| 2 Jahre |
| Sarah G. Roth | F | - |
Kellogg School of Management
| 2 Jahre |
| Christopher Ackerman | M | - |
Kellogg School of Management
| 2 Jahre |
| Chris Flynn | M | 50 |
Kellogg School of Management
| 2 Jahre |
| Tian Ruo Pu | M | 55 |
Kellogg School of Management
| 2 Jahre |
| Theo Brito | M | - |
Kellogg School of Management
| 2 Jahre |
| Andrew Hamer | M | 62 | 6 Jahre | |
| Carlos Miguel Botelho | M | - |
Kellogg School of Management
| 1 Jahre |
| Thomas W. Giacomini | M | 58 |
Kellogg School of Management
| 2 Jahre |
| Jon Leiman | M | - |
Kellogg School of Management
| 1 Jahre |
| James Cherry | M | - |
Kellogg School of Management
| 3 Jahre |
| Rahul Mahinder Kumar Khanna | M | - |
Kellogg School of Management
| 2 Jahre |
| Sumant Mandal | M | 54 |
Kellogg School of Management
| 2 Jahre |
| Jonathon Nudi | M | 53 |
Kellogg School of Management
| 2 Jahre |
| Jill Jortner | F | - |
Kellogg School of Management
| 2 Jahre |
| Bill A. Lundstrom | M | - |
Kellogg School of Management
| 2 Jahre |
| Erin L. Lydon | F | 54 |
Kellogg School of Management
| 2 Jahre |
| Anu Singh | M | 51 |
Kellogg School of Management
| 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 88 | 88,00% |
| Schweiz | 12 | 12,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Grace Larry
- Persönliches Netzwerk
